Anti-Mouse CD4 (Clone YTS191) – Purified in vivo PLATINUM™ Functional Grade

Clone YTS191 is primarily used in in vivo mouse studies to selectively deplete CD4+ T cells, which are critical components of the immune system, including helper T cells and regulatory T cells. Researchers administer this monoclonal antibody to mice, where it binds to the CD4 glycoprotein on target cells and facilitates their removal, allowing investigation of the role of CD4+ T cells in specific immune processes and disease models.

Key uses in in vivo mouse studies include:

• Depletion of CD4+ T cells: By targeting the CD4 molecule, YTS191 induces the loss of these cells from the circulation and tissues, providing a tool to assess their contribution to immune responses, disease progression, or therapeutic interventions.
• Functional immunology research: Removal or neutralization of CD4+ cells helps elucidate mechanisms in autoimmunity, infection, transplant tolerance, and tumor immunology.
• Preclinical modeling: YTS191 is often administered at high purity and low endotoxin formulations for experimental consistency and to minimize off-target effects or inflammatory artifacts.
• Other applications: While in vivo depletion is the major use, this clone is also applicable in flow cytometry, immunohistochemistry, and ELISA as a reagent for identifying or quantifying CD4+ cells.

Important experimental details:

• YTS191 is a rat monoclonal antibody of the IgG2b isotype, formulated for in vivo use with minimal endotoxin contamination (<1.0 EU/mg), critical for avoiding nonspecific immune activation in mice.
• CD4 is expressed on a majority of thymocytes, MHC class II-restricted T cells, some natural killer T cells, dendritic cells, and macrophages; depleting with YTS191 will therefore affect all these cell populations, not solely conventional helper T cells.
• Depleting activity of YTS191 in vivo has been documented and referenced in immunological literature and manufacturer datasheets.

In summary, YTS191 is a validated tool for the depletion and functional analysis of CD4+ cells in vivo, enabling the study of their roles in the mouse immune system and various disease states.

YTS191 is a monoclonal antibody specific for mouse CD4, commonly used for CD4+ T cell depletion and functional studies in vivo. In the literature, when YTS191 is used, several other antibodies or proteins are frequently employed alongside it to characterize immune subsets, controls, or as experimental comparators. Commonly used antibodies/proteins include:

• Anti-mouse CD8 antibodies (e.g., clone YTS169, 53-6.7, or 2.43): Used for depleting or identifying CD8+ T cells in parallel with CD4+ T cell studies.
• Anti-mouse CD3 antibodies: As a pan-T cell marker, for identifying or depleting all T cells.
• Anti-mouse CD25 (IL-2R?): Used to target regulatory T cells.
• Isotype control antibodies (e.g., rat IgG2b isotype controls): For experimental specificity and background signal assessment.
• Anti-mouse NK1.1 or CD49b (DX5) antibodies: For depleting or identifying NK cells, especially in combined depletion experiments.
• Anti-mouse CD45 (pan-leukocyte marker) and lineage markers (e.g., CD11b for myeloid, B220 for B cells) for comprehensive immune phenotyping.

These antibodies are often employed together in protocols such as:

• T cell subset depletion experiments to compare the roles of CD4+, CD8+, and NK cells.
• Flow cytometry panels to characterize T cell populations and confirm depletion efficacy.
• Isotype controls are nearly always recommended as direct comparators to YTS191 for rigorous experimental interpretation.

The combination of these antibodies depends on the experimental design but CD8 and isotype controls are the most frequent companions of YTS191 in the literature. This is consistent across suppliers’ recommendations and published depletion protocols.

Clone YTS191 is a widely used rat monoclonal antibody that specifically targets mouse CD4, a cell surface antigen found on thymocytes and helper/inducer T cells. The key findings from scientific literature regarding this clone include its application in cell identification, depletion, and immune modulation studies:

• Target and Specificity: YTS191 recognizes murine CD4, facilitating the identification and isolation of CD4+ T cell populations for immunological studies.
• Functional Use: YTS191 is used both as a research reagent for flow cytometry (e.g., when conjugated to fluorophores in dual-color cocktails for simultaneous detection of CD4 and CD8) and as a depleting antibody in vivo, effectively reducing CD4+ T cell counts in treated mice.
• Experimental Protocols: YTS191’s depleting activity has made it a standard tool in mouse models to selectively ablate CD4+ T cells, which helps study the impact of CD4+ T cell removal on various immunological processes, including immune responses, tolerance mechanisms, and the effects of checkpoint inhibitor combinations.

Additional details:

• YTS191 is most often used alongside other antibodies (such as KT15 for CD8 detection) for dual-color flow cytometry setups, allowing researchers to analyze T cell subsets efficiently.
• When used in vivo, YTS191 is noted for reliably, specifically depleting CD4+ T cells without widespread non-specific effects.
• This clone is cited across immunology research for applications ranging from basic T cell biology to in-depth analysis of immune modulation in disease models.

Summary Table:

No conflicting data were found in the cited literature; all sources agree on the key attributes and applications of the YTS191 clone. There is limited evidence concerning the detailed mechanistic effects of YTS191 beyond depletion, as most literature focuses on its use as a technical reagent for cell removal or detection.

Dosing regimens for clone YTS191 (rat anti-mouse CD4-depleting antibody) in mouse models generally range from 100?µg (low dose) to 1?mg (high dose) per mouse administered as a single injection, with the precise dose chosen depending on experimental goals and the disease model employed.

• In studies using LCMV-Cl13 infection models (chronic viral infection), both uninfected and infected mice received either a low dose of 100?µg or a high dose of 1?mg of YTS191 by the indicated route (not specified in the search results, but usually intraperitoneal or intravenous), with efficacy assessed 5 days post-administration.
• The low dose (100?µg) and high dose (1?mg) regimens produced dose-dependent depletion of CD4? T cells in both spleen and blood.
• No evidence was seen in the available results for substantially different dosing strategies across different mouse models—most regimens for YTS191 employ single bolus doses within this range for in vivo depletion studies.
• Some suppliers report solutions at 1?mg/ml concentration, consistent with the in vivo use described above.

Additional Important Details

• Experimental context (e.g., infection, tumor, autoimmunity) and mouse strain may influence whether low or high dose is used, but the fundamental dosing range remains 100?µg to 1?mg per mouse.
• Follow-up measurement of CD4? T cell depletion is typically done 5 days after antibody administration, allowing comparison to isotype controls.
• Clone YTS191.1 is commonly used as a depleting antibody in immunological studies to selectively ablate CD4? T cells in vivo.

Comparison to Other Antibody Dosing Regimens

For context, other immunotherapy antibodies (e.g., anti-PD-1, anti-CTLA-4) are typically dosed between 100–500?µg per mouse, given every 3–4 days, but YTS191’s regimen is usually a single bolus.

In summary: The dosing of YTS191 across diverse mouse models consistently falls in the 100?µg to 1?mg per mouse range, administered as a single dose, with slight variations tailored to depletion needs and experimental design.